We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Read MoreHide Full Article
Key Takeaways
SRRK shares surged 14% after resubmitting its FDA filing for SMA drug apitegromab.
The resubmission addresses prior manufacturing issues and adds a second fill-finish facility.
Apitegromab showed significant motor function gains and could become SRRK's first marketed product.
Shares of Scholar Rock (SRRK - Free Report) rose 14% on Tuesday after the company announced the resubmission of a regulatory filing to the FDA, seeking approval for its investigational muscle-targeted therapy, apitegromab, to treat spinal muscular atrophy (SMA) in children and adults.
The company expects the agency to accept this filing within 30 days, and a review period of up to six months from the resubmission date. If accepted, SRRK anticipates a final decision in September 2026.
Scholar Rock had initially submitted this filing last year, which was granted priority review. The FDA issued a complete response letter (CRL) to the BLA in September, citing observations at Catalent’s Indiana fill-finish facility, owned by pharma giant Novo Nordisk. This CRL was not related to concerns around apitegromab’s efficacy or safety, suggesting that the core clinical profile remains intact.
Since then, Scholar Rock has worked with the FDA and the Catalent site to address the deficiencies. The resubmitted filing includes a second U.S.-based fill-finish facility, which should help strengthen supply chain reliability and support future commercial demand.
Both the original and resubmitted filings are supported by data from a pivotal late-stage study, which showed that treatment with apitegromab achieved statistically significant and clinically meaningful improvements in motor function in SMA patients. A similar filing is under review in the EU, with a final decision expected in mid-2026.
If approved, Scholar Rock’s apitegromab will compete with large pharmaceutical companies. This includes Biogen’s (BIIB - Free Report) injectable drug Spinraza, Novartis’ (NVS - Free Report) gene therapy Zolgensma and Roche’s (RHHBY - Free Report) oral drug Evrysdi. These treatments currently dominate the SMA market and have generated blockbuster sales, highlighting the significant commercial opportunity in this space.
SRRK Stock Performance
Shares of Scholar Rock rose in response to the above announcement, as investors welcomed the resolution of prior regulatory hurdles and the renewed path toward potential approval.
The company currently has no approved or marketed products. If apitegromab secures FDA approval, it would mark the company’s first commercial product, enabling it to generate a recurring revenue stream. The potential launch would represent a key inflection point, transforming SRRK from a clinical-stage biotech into a commercial-stage company.
Year to date, the stock has risen nearly 12% compared with the industry‘s 4% growth.
Image Source: Zacks Investment Research
More on SRRK’s Apitegromab
Apitegromab is a fully human monoclonal antibody designed to inhibit the activation of myostatin, a protein primarily produced in skeletal muscle cells that acts as a negative regulator of muscle growth. By blocking myostatin signaling, the therapy aims to improve muscle strength and function in patients with neuromuscular disorders.
Apart from SMA, Scholar Rock is currently evaluating apitegromab for the treatment of people with a rare neuromuscular disease called facioscapulohumeral muscular dystrophy (FSHD). It expects to start a mid-stage study on the drug in this indication later this year.
View the Zacks #1 Rank List
Image: Bigstock
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Key Takeaways
Shares of Scholar Rock (SRRK - Free Report) rose 14% on Tuesday after the company announced the resubmission of a regulatory filing to the FDA, seeking approval for its investigational muscle-targeted therapy, apitegromab, to treat spinal muscular atrophy (SMA) in children and adults.
The company expects the agency to accept this filing within 30 days, and a review period of up to six months from the resubmission date. If accepted, SRRK anticipates a final decision in September 2026.
Scholar Rock had initially submitted this filing last year, which was granted priority review. The FDA issued a complete response letter (CRL) to the BLA in September, citing observations at Catalent’s Indiana fill-finish facility, owned by pharma giant Novo Nordisk. This CRL was not related to concerns around apitegromab’s efficacy or safety, suggesting that the core clinical profile remains intact.
Since then, Scholar Rock has worked with the FDA and the Catalent site to address the deficiencies. The resubmitted filing includes a second U.S.-based fill-finish facility, which should help strengthen supply chain reliability and support future commercial demand.
Both the original and resubmitted filings are supported by data from a pivotal late-stage study, which showed that treatment with apitegromab achieved statistically significant and clinically meaningful improvements in motor function in SMA patients. A similar filing is under review in the EU, with a final decision expected in mid-2026.
If approved, Scholar Rock’s apitegromab will compete with large pharmaceutical companies. This includes Biogen’s (BIIB - Free Report) injectable drug Spinraza, Novartis’ (NVS - Free Report) gene therapy Zolgensma and Roche’s (RHHBY - Free Report) oral drug Evrysdi. These treatments currently dominate the SMA market and have generated blockbuster sales, highlighting the significant commercial opportunity in this space.
SRRK Stock Performance
Shares of Scholar Rock rose in response to the above announcement, as investors welcomed the resolution of prior regulatory hurdles and the renewed path toward potential approval.
The company currently has no approved or marketed products. If apitegromab secures FDA approval, it would mark the company’s first commercial product, enabling it to generate a recurring revenue stream. The potential launch would represent a key inflection point, transforming SRRK from a clinical-stage biotech into a commercial-stage company.
Year to date, the stock has risen nearly 12% compared with the industry‘s 4% growth.
Image Source: Zacks Investment Research
More on SRRK’s Apitegromab
Apitegromab is a fully human monoclonal antibody designed to inhibit the activation of myostatin, a protein primarily produced in skeletal muscle cells that acts as a negative regulator of muscle growth. By blocking myostatin signaling, the therapy aims to improve muscle strength and function in patients with neuromuscular disorders.
Apart from SMA, Scholar Rock is currently evaluating apitegromab for the treatment of people with a rare neuromuscular disease called facioscapulohumeral muscular dystrophy (FSHD). It expects to start a mid-stage study on the drug in this indication later this year.
Scholar Rock Holding Corporation Price
Scholar Rock Holding Corporation price | Scholar Rock Holding Corporation Quote
SRRK’s Zacks Rank
Scholar Rock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.